Detalhe da pesquisa
1.
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
Diabetes Obes Metab
; 23(2): 569-580, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33185002
2.
Baseline characteristics of patients enrolled in the EMPACT-MI trial.
Eur J Heart Fail
; 25(9): 1708-1715, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37622416
3.
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Lancet Diabetes Endocrinol
; 2(9): 691-700, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24948511